Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma

Clinical Cancer Research

Volumn 15, Issue 19, 2009, Pages 5956-5961

  Evageliou, Nicholas F ^a   Hogarty, Michael D ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMIDINOINDAN 1 ONE 2 AMIDINHYDRAZONE; ANTINEOPLASTIC AGENT; CISPLATIN; DEXTRO LYSINE SPERMINE; EFLORNITHINE; F 14512; MQT 1426; N 1 SPERMYLLYSINAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ORI 202; PG 11047; PODOPHYLLOTOXIN PLUS SPERMINE; POLYAMINE; SAM 486; SPERMINE DERIVATIVE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER SURVIVAL; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; HOMEOSTASIS; HUMAN; LUNG NON SMALL CELL CANCER; NEUROBLASTOMA; NONHUMAN; ONCOGENE MYC; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; TREATMENT REFUSAL; TRYPANOSOMIASIS; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HOMEOSTASIS; HUMANS; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NEUROBLASTOMA; POLYAMINES;

EID: 70349690458     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3213     Document Type: Review

References (61)

1. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005;6:635-645, PubMed. (Pubitemid 41081267)
2. Fernandez PC, Frank SR, Wang L, et al. Genomic targets of the human c-Myc protein. Genes Dev 2003;17:1115-1129, PubMed. (Pubitemid 36534986)
3. O'Connell BC, Cheung AF, Simkevich CP, et al. A large scale genetic analysis of c-Myc-regulated gene expression patterns. J Biol Chem 2003;278: 12563-12573, PubMed.
4. Chang TC, Yu D, Lee YS, et al. Widespread micro- RNA repression by Myc contributes to tumorigenesis. Nat Genet 2008;40:43-50, PubMed.
5. Knoepfler PS, Zhang XY, Cheng PF, Gafken PR, McMahon SB, Eisenman RN. Myc influences global chromatin structure. EMBO J 2006;25: 2723-2734, PubMed.
6. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 1993;5:56-61. (Pubitemid 23261519)
7. Soucek L, Whitfield J, Martins CP, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008;455:679-683, PubMed.
8. Boon K, Caron HN, van Asperen R, et al. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J 2001;20:1383-1393, PubMed. (Pubitemid 32233978)
9. Osthus RC, Shim H, Kim S, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000;275:21797-21800, PubMed. (Pubitemid 30621745)
10. Wise DR, DeBerardinis RJ, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 2008;105:18782-18787, PubMed.
11. Thomas T, Thomas TJ. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 2001;58:244-258, PubMed. (Pubitemid 32217356)
12. Andersson G, Heby O. Polyamine and nucleic acid concentrations in Ehrlich ascites carcinoma cells and liver of tumor-bearing mice at various stages of tumor growth. J Natl Cancer Inst 1972; 48:165-172, PubMed.
13. Russell D, Snyder SH. Amine synthesis in rapidly growing tissues: ornithine decarboxylase activity in regenerating rat liver, chick embryo, and various tumors. Proc Natl Acad Sci U S A 1968;60:1420-1427, PubMed.
14. Casero RA, Jr., Marton LJ. Targeting polyaminemetabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 2007;6:373-390, PubMed.
15. Gerner EW, Meyskens FL, Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004;4:781-792, PubMed.
16. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci U S A 1993;90:7804-7808, PubMed. (Pubitemid 23250039)
17. Moshier JA, Dosescu J, Skunca M, Luk GD. Transformation of NIH/3T3 cells by ornithine decarboxylase overexpression. Cancer Res 1993; 53:2618-2622, PubMed. (Pubitemid 23168032)
18. Smith MK, Trempus CS, Gilmour SK. Co-operation between follicular ornithine decarboxylase and v-Ha-ras induces spontaneous papillomas and malignant conversion in transgenic skin. Carcinogenesis 1998;19:1409-1415, PubMed.
19. Basuroy UK, Gerner EW. Emerging concepts in targeting the polyamine metabolic pathway in epithelial cancer chemoprevention and chemotherapy. J Biochem 2006;139:27-33.
20. Matsufuji S, Matsufuji T, Miyazaki Y, et al. Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme. Cell 1995;80:51-60, PubMed.
21. Koguchi K, Kobayashi S, Hayashi T, Matsufuji S, Murakami Y, Hayashi S. Cloning and sequencing of a human cDNA encoding ornithine decarboxylase antizyme inhibitor. Biochim Biophys Acta 1997;1353:209-216, PubMed. (Pubitemid 27439194)
22. Kanerva K, Makitie LT, Pelander A, Heiskala M, Andersson LC. Human ornithine decarboxylase paralogue (ODCp) is an antizyme inhibitor but not an arginine decarboxylase. Biochem J 2008;409:187-192, PubMed.
23. Albeck S, Dym O, Unger T, Snapir Z, Bercovich Z, Kahana C. Crystallographic and biochemical studies revealing the structural basis for antizyme inhibitor function. Protein Sci 2008;17: 793-802, PubMed. (Pubitemid 351629574)
24. Xiao L, Celano P, Mank AR, Pegg AE, Casero RA, Jr. Characterization of a full-length cDNA which codes for the human spermidine/spermine N1-acetyltransferase. Biochem Biophys Res Commun 1991;179:407-415, PubMed.
25. Uemura T, Yerushalmi HF, Tsaprailis G, et al. Identification and characterization of a diamine exporter in colon epithelial cells. J Biol Chem 2008;283:26428-26435, PubMed.
26. Cooper HL, Park MH, Folk JE,Safer B, Braverman R. Identification of the hypusine-containing protein hy+ as translation initiation factor eIF-4D. Proc Natl Acad Sci U S A 1983;80:1854-1857, PubMed.
27. Pless M, Belhadj K, Menssen HD, et al. Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter study.Clin Cancer Res 2004;10:1299-1305, PubMed.
28. Siimes M, Seppanen P, Alhonen-Hongisto L, Janne J. Synergistic action of two polyamine antimetabolites leads to a rapid therapeutic response in childhood leukemia. Int J Cancer 1981;28:567-570, PubMed. (Pubitemid 11030486)
29. Levin VA, Hess KR, Choucair A, et al. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine- PCV versus PCV for anaplastic gliomas. Clin Cancer Res 2003;9:981-990, PubMed. (Pubitemid 36323701)
30. Maris JM,Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-2120, PubMed.
31. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-1124, PubMed. (Pubitemid 14106392)
32. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-1116, PubMed. (Pubitemid 16216827)
33. Fredlund E, Ringner M, Maris JM, Pahlman S. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci U S A 2008;105:14094-14099, PubMed.
34. Liu X, Mazanek P, Dam V, et al. Deregulated Wnt/B-catenin program in high-risk neuroblastomas without MYCN amplification. Oncogene 2008;27:1478-1488, PubMed. (Pubitemid 351317458)
35. Westermann F, Muth D, Benner A, et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 2008;9:R150, PubMed.
36. Zhu C, Lang DW, Coffino P. Antizyme2 is a negative regulator of ornithine decarboxylase and polyamine transport. J Biol Chem 1999;274: 26425-26430, PubMed. (Pubitemid 129520076)
37. Hogarty MD, Norris MD, Davis K, et al. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 2008;68:9735-9745, PubMed.
38. Rounbehler RJ, Li W, Hall MA, Yang C, Fallahi M, Cleveland JL. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res 2009;69:547-553, PubMed.
39. Guo Y, Harris RB, Rosson D, Boorman D, O'Brien TG. Functional analysis of human ornithine decarboxylase alleles. Cancer Res 2000; 60:6314-6317, PubMed. (Pubitemid 30952130)
40. Martinez ME, O'Brien TG, Fultz KE, et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci U S A 2003;100:7859-7864, PubMed.
41. Haber M, Cheng N, Smith J, et al. Overexpression of ODC1 is associated with poor outcome in childhood neuroblastoma and represents an important therapeutic target [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008 Apr 12-16; San Diego, CA. Philadelphia (PA): AACR; 2008. Abstract 5832.
42. Hansford LM, Thomas WD, Keating JM, et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci U S A 2004;101: 12664-12669, PubMed.
43. Weiss WA, Aldape K, Bishop JM. Targeted expression of NMYC causes neuroblastoma in transgenic mice. EMBO J 1997;16:2985-2995, PubMed. (Pubitemid 27234938)
44. Chesler L, Goldenberg DD, Seales IT, et al. Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res 2007;67:9435-9442, PubMed. (Pubitemid 47541995)
45. Nilsson JA, Keller UB, Baudino TA, et al. Targeting ornithine decarboxylase in Mycinduced lymphomagenesis prevents tumor formation. Cancer Cell 2005;7:433-444, PubMed.
46. Wallick CJ, Gamper I, Thorne M, et al. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest inMYCN-amplifiedhuman neuroblastoma cells. Oncogene 2005;24:5606-5618, PubMed. (Pubitemid 43119354)
47. Evageliou NF, Vu A, Davis K, et al. Dual targeting of AMD1 and ODC1 potently inhibits neuroblastoma initiation in vitro and in vivo [abstract]. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract 3203.
48. Koomoa DL, Yco LP, Borsics T, Wallick CJ, Bachmann AS. Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma. Cancer Res 2008;68:9825-9831, PubMed.
49. Seiler N, Delcros JG, Moulinoux JP. Polyamine transport in mammalian cells. An update. Int J Biochem Cell Biol 1996;28:843-861, PubMed. (Pubitemid 26284212)
50. Weeks RS, Vanderwerf SM, Carlson CL, et al. Novel lysine-spermine conjugate inhibits polyamine transport and inhibits cell growth when given with DFMO. Exp Cell Res 2000;261:293-302, PubMed.
51. Chen Y, Weeks RS, Burns MR, Boorman DW, Klein-Szanto A, O'Brien TG. Combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma. Int J Cancer 2006; 118:2344-2349, PubMed.
52. Barret JM, Kruczynski A, Vispe S, et al. F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system. Cancer Res 2008;68: 9845-9853, PubMed.
53. Babbar N, Ignatenko NA, Casero RA, Jr., Gerner EW. Cyclooxygenase- independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem 2003;278:47762-47775, PubMed. (Pubitemid 37523223)
54. Meyskens FL, McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008;1:32-38.
55. Varma R, Hector S, Greco WR, et al. Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration- effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells. Cancer Chemother Pharmacol 2007;59: 711-723, PubMed. (Pubitemid 46440593)
56. Kramer DL, Diegelman P, Jell J, Vujcic S, Merali S, Porter CW. Polyamine acetylation modulates polyamine metabolic flux, a prelude to broader metabolic consequences. J Biol Chem 2008;283:4241-4251, PubMed.
57. Hacker A, Marton LJ, Sobolewski M, Casero RA, Jr. In vitro and in vivo effects of the conformationally restricted polyamine analogue CGC-11047 on small cell and non-small cell lung cancer cells. Cancer Chemother Pharmacol 2008; 63:45-53, PubMed.
58. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007;49:928-940, PubMed. (Pubitemid 350022448)
59. Maris JM, Courtright J, Houghton PJ, et al. Pediatric Preclinical Testing Program (PPTP) evaluation of the novel polyamine analogue PG11047 [abstract]. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract 3194.
60. Saini P, Eyler DE, Green R, Dever TE. Hypusine containing protein eIF5A promotes translation elongation. Nature 2009;459:118-121, PubMed.
61. Seiler N, Raul F. Polyamines and apoptosis. J Cell Mol Med 2005;9:623-642, PubMed.